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Introduction:  This multi-center,  hospital-based  observational  study  determined  the  seroprevalence  of
pertussis  antibodies  amongst  healthcare  professionals  from  three  different  hospitals  in Spain  to  ascertain
the  health  status  of  professionals  attending  to susceptible  groups  who  are  at  risk  of contracting  and
transmitting  pertussis.
Methods:  Medical  professionals  from  three  hospitals  in  Spain  were  recruited  for  this  study
(NCT01706224).  Serum  samples  from  subjects  were  assessed  for anti-pertussis  antibodies  by ELISA.
The percentage  of  subjects  positive  for anti-pertussis  antibodies  were determined  by  age-strata,  gen-
der, vaccination  status,  professional  level  (physicians,  nurses,  ancillary  nurses  and  midwives),  hospital
department,  number  of  working  years,  numbers  of  hours  spent  with  the  patient  as  well as  number  of
children in the  household.
Results: Overall,  31.2%  of  subjects  were seropositive;  3.3%  of  these  healthcare  professionals  had  ELISA
values  indicative  of  current  or recent  infection.  There  were  no signiﬁcant  differences  in  terms  of  pertussis
prevalence  with  respect  to age,  gender,  hospital  department,  profession,  number  of  working  years  and
ith  panumber  of  hours  spent  w
strengthen  the rationale  for va
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1. Introduction
Pertussis, caused by Bordetella pertussis (B. pertussis) is a highly
contagious respiratory disease, primarily affecting infants and
young children and it is estimated that, worldwide, pertussis results
in over 16 million cases and 195,000 deaths annually [1,2].
Primary pertussis vaccination has been implemented in the
National Immunization Programs of most countries and developed
countries have high coverage rates for infants [3].
In Spain, universal vaccination with the whole-cell pertus-
sis vaccine combined with tetanus and diphtheria vaccine was
introduced in 1965, with vaccine coverage reaching 94% in 1997,
and pertussis became a notiﬁable disease in 1982 [3]. Between 1982
and 1999, morbidity due to pertussis decreased by 95% and from
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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hen on it has remained stable. In 2000, the annual incidence of per-
ussis was less than 1.5 cases per 100,000 persons [4]; however, by
011, pertussis incidence reached 5.52 cases per 100,000 persons
5] with over 40% of cases being infants under one year, adolescents
epresenting more than 14.6%, and adults representing 12.4% [4,6].
While the introduction of pertussis vaccination has greatly
educed the incidence and mortality due to whooping cough in
nfants, it has however been reported that waning of pertussis
mmunity occurs 4–12 years after vaccination or 4–20 years after
atural infection [7–9].
Previous studies have shown that adolescents and adults serve
s a major reservoir of pertussis infection which has led to an
ncrease in the incidence of pertussis over the last 30 years in this
opulation, particularly in the United States and Europe [9,10].
Within the general population, healthcare professionals form
n important subset as they may  act as vectors facilitating the
ransmission of pertussis amongst their patients, especially in
mmunosuppressed individuals. At the hospital level, the trans-
ission of pertussis may  occur between visitors and patients and
etween healthcare personnel and patients, or vice versa [11–14].
Given the risk of transmission to the most vulnerable popula-
ions in the hospitals (newborns, premature babies, etc.) [11–13],
everal countries have recommended vaccination to healthcare
orkers. Indeed, several nosocomial outbreaks have been reported
nvolving health professionals showing how real the risk is and for
his reason [6,11–15], several countries emphasize the importance
f vaccination against pertussis amongst healthcare personnel,
specially in Pediatric and Obstetric Departments.
According to the World Health Organization, a single dose of
etanus-Diphtheria-acellular Pertussis (Tdap) vaccine is recom-
ended for healthcare personnel who have not previously received
dap as an adult and who have direct patient contact. In order to
educe the transmission of pertussis amongst children in whom
he illness might be associated with serious complications, vac-
ination against pertussis has been recommended in Spain since
004 for medical professionals caring for premature infants and
hose requiring hospitalization [16], and since 2011 for all mem-
ers of staff working in Pediatric and Obstetric Departments [17].
he following are the recommendations of the Advisory Commit-
ee on Immunization Practices (ACIP) in 2011: Regardless of age,
ealthcare personnel should receive a single dose of Tdap as soon
s feasible if they have not previously received Tdap and regardless
f the time since their most recent tetanus-diphteria vaccination
18].
Different vaccination policies and programs are applied by the
ospitals included in this study. Since 2009, a Tdap booster is
ffered to all healthcare professionals working with children at the
ospital Universitario Puerta de Hierro, Madrid (HUPdH). Three
ears ago, this has been extended to include all personnel. All
ealthcare professionals working at the Complejo Hospitalario Uni-
ersitario, A Corun˜a (CHUAC) were offered a Tdap booster for the
ast 10 years. However, since 2011, vaccination is rigorously imple-
ented amongst personnel working in pediatrics, obstetrics and
mergency areas, and pregnant professionals working in clean
reas, following outbreaks of severe cough. There is no systematic
accination program in place for personnel at the Hospital Uni-
ersitario de Bellvitge, Barcelona (HUdB) as Department of Health
oes not provide the vaccine neither authorize its use for healthcare
rofessionals.
Nonetheless, pertussis vaccination coverage ratios amongst
ealthcare personnel are still very low and many of these profes-
ionals are suspected to be susceptible [19].The aim of this study was to determine the seroprevalence
f pertussis antibodies amongst healthcare personnel in different
ospital centers in Spain. This will help determine the cur-
ent level of susceptibility of healthcare personnel to contract accine 34 (2016) 1109–1114
disease that could be transmitted to vulnerable groups at risk of
suffering severe forms of the disease with a potential risk of fatal
outcome.
2. Materials and methods
2.1. Study design and methods
This multi-center, hospital based seroprevalence study
(NCT01706224) was  carried out between 22 November 2012
and 28 May  2013, in three hospitals in Spain – HUPdH, CHUAC and
HUdB.
Healthcare personnel from different professional levels (physi-
cians from different specialties, nurses, ancillary nurses and
midwives) who were ≥18 years of age were eligible to be enrolled in
the study. HUPdH and CHUAC had a population which included all
four professional levels, while HUdB excluded midwives. Based on
data provided by the participating hospitals, distribution amongst
the various healthcare groups was  as follows: 30.3% (n = 229) physi-
cians, 39.6% (n = 300) nurses, 26.7% (n = 202) ancillary nurses and
3.4% (n = 26) midwives.
Socio-demographic characteristics such as age, gender, data on
pertussis vaccination, and infection history were collected. This
information was  collected exclusively during the interviews with
the participants. The study was  approved by each hospital’s ethics
committee, assessed by competent authorities and was conducted
in accordance with Good Clinical Practice and the Declaration of
Helsinki. Written informed consent was obtained from all partici-
pants who were enrolled.
2.2. Antibody assay
Serum samples were taken from all enrolled participants and
stored at −20 ◦C until they were tested at the Instituto Valenciano
de Microbiología (Valencia, Spain). Immunoglobulin G (IgG) anti-
bodies to B. pertussis toxin (PT) were determined by a commercially
available Enzyme Linked Immunosorbent Assay kit (ELISA, PER-
TUSSCAN PT IgG, Euro Diagnostica AB, Sweden).
The participant was  considered seronegative if the anti-PT
IgG levels were ≤0.3 optical density (OD), seropositive if the
anti-PT IgG levels >0.3 OD. Participants with anti-PT antibody lev-
els ≥1.0 OD were indicative of recent/current pertussis infection.
These cut-off points were in accordance with the manufacturer
guidelines. The assay detected an OD ≥1.0 with 98.1% sensitiv-
ity (95% conﬁdence interval [CI] = 89.7–100%) and 97.2% speciﬁcity
(95% CI = 92.0–99.4%), while the assay detected an OD ≥1.5 with
82.7% sensitivity (95% CI = 69.7–91.8%) and 99.1% speciﬁcity (95%
CI = 94.9–100%) [20].
2.3. Statistical analysis
Analysis was performed on all participants who met  the eligi-
bility criteria. The target enrolment was 756 participants based on
the assumption that anti-PT IgG was detected in 50% of healthcare
personnel [21].
The prevalence of pertussis antibodies was  assessed by age
groups (18–24 years, 25–34 years, 35–44 years and ≥45 years),
gender, professional level (physicians, nurses, ancillary nurses and
midwives), type of hospital department (pediatrics, neonatology,
obstetrics, internal medicine, surgery and other departments) the
participant was  working in, the percentage of labor time spent with
patients (≤25% of time, >25–50%, >50–75% and >75%) and dura-
tion of service of healthcare personnel in healthcare centers. The
differences in the prevalence of pertussis antibodies based on clas-
siﬁcations given above were calculated by the chi-square or Fisher’s
exact test.
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Table  1
Demographic characteristics.
Characteristics Categories Physicians N = 219 Nurses N = 292 Ancillary Nurses N = 198 Midwives N = 22 Total N = 731
n % n %a n % n %a n %
Age (Years) at
enrolment
Mean 38.7 – 45.2 – 47.3 – 38.5 – 43.6 –
SD  12.6 – 11.1 – 11.3 – 8.9 – 12.1 –
Age  group 18–24y 27 12.3 4 1.4 10 5.1 1 4.6 42 5.8
25–34y 79 36.1 52 17.8 20 10.1 7 31.8 158 21.6
35–44y 44 20.1 82 28.1 44 22.2 10 45.5 180 24.6
≥45y  69 31.5 154 52.7 124 62.6 4 18.2 351 48.0
Gender Female 125 57.0 264 90.4 192 97.0 20 90.9 601 82.2
Labor  time spent
in contact with
patients (%)
≤25% 11 5.0 8 2.7 2 1.0 0 0.0 21 2.9
>25  to 50% 25 11.4 8 2.7 5 2.5 0 0.0 38 5.2
>50  to 75% 49 22.4 31 10.6 18 9.1 8 36.4 106 14.5
>75%  134 61.2 245 83.9 173 87.4 14 63.6 566 77.4
n
e
o
p
3
3
d
F
s
T
p
k
c
3
c
w, number in each category; % = (n/N) × 100; SD, standard deviation; y, years.
a Sum of percentages may  not be 100% due to rounding.
The household composition of the healthcare personnel
nrolled was also taken into account to identify the proportion
f healthcare personnel who were at a higher risk for contracting
ertussis.
. Results
.1. Study population
Primarily, 757 participants were screened and analysis was con-
ucted on 731 participants. Reasons for exclusion are shown in
ig. 1. The mean age of participants included in the ﬁnal analy-
is was 43.6 years (range: 20–69) and 82.2% (n = 601) were female.
he demographics are detailed in Table 1.
Median number of years of service was 10.0. In 40% of the study
opulation, vaccination status was unknown. From the 439 with
nown status, 339 conﬁrmed previous vaccination, but only 4.13%
onﬁrmed a vaccination during adulthood.
.2. Seroprevalence of pertussis antibodies, overall and by subject
haracteristics
Of the 731 participants included in the ﬁnal analysis, 503 (68.8%)
ere seronegative and 228 (31.8%) were seropositive. Amongst the
757 Pa
229 healthcare physicians
300 nurses
202 ancillary nurses
26 midwives
756 – Total cohor t
229 healthcare physicians
299 nurses
202 ancillary nurses
26 midwives
1 nurse withdrew 
consent
731 – According-to-protocol cohort
219 healthcare physicians
292 nurses
198 ancillary nurses
22 midwives
Reasons for 
Exclusion
a) 1 nurse had 
esse al serological 
data missing.
b) 10 physicians, 6 
nurses, 4 ancillary 
nurses and 4 
midwives were 
vaccinated for 
pertussis in previous 
12 months
Fig. 1. Participant enrollment chart.seropositive participants, 24 (3.3%) had values ≥1.0 OD,  and 5 (0.7%)
had values ≥1.5 OD.
No difference in seroprevalence was  found by age group and
gender. A signiﬁcant difference was found when classifying by the
number of children >5 years living in the same house. Seropreva-
lence was 30.62, 23.76, 40.30 and 72.73% when living with 0, 1, 2
or 3 or more children, respectively (p = 0.0028).
No difference was  found when looking at the history of pertus-
sis disease or vaccination status, although vaccination information
was unknown in 40% of the subjects.
3.3. Seroprevalence of pertussis antibodies by professional
characteristics (Table 2)
The seroprevalence by professional characteristics is described
in Table 2. There were no signiﬁcant differences seen in seroposi-
tivity by hospital, department or professional category.
4. Discussion
Our results show that around 68.8% of hospital healthcare
professionals have no anti-PT antibodies and therefore might be
susceptible of being infected by pertussis. This is not the ﬁrst study
speciﬁcally addressing this topic but it shows a higher seronega-
tivity proportion when compared with other studies conducted in
Spain [19,21–24] or elsewhere [25,26].
For example in Catalonia, Urbiztondo et al. [19] found that half
of the healthcare personnel examined were susceptible to pertus-
sis infection, as the prevalence of anti-PT antibodies was found to
be 52% amongst the healthcare personnel evaluated. In Madrid, de
Juanes et al. [21] also found that 50% of the population studied
(physicians and nursing personnel) were seronegative for pertus-
sis tested using antibodies against whole B. pertussis. Ortega et al.
[22], in Madrid, also observed similar global prevalence of 56% for
anti-whole B. pertussis antibodies (60% amongst males and 54.5%
amongst females). A much older study conducted on a cross-section
of the Spanish population between 1992 and 1993 showed a sero-
prevalence of anti-PT antibodies in 46% of the population [23] while
another study conducted in Catalonia in 1996 showed a seropreva-
lence of 75% of anti-PT antibodies [24].
The ﬁgures from outside Spain are not very different from those
reported above: Higa et al. [25] found 43.8% of anti-PT antibodies in
the healthcare personnel of a hospital in Japan while Hashemi et al.
[26] found a prevalence of anti-PT antibodies in 47.6% of Iranian
medical students. These results need to be compared with great
caution since there are various differences that arise due to ELISA
kit speciﬁcities as well as the antigens used.
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Table 2
Seroprevalence by professional characteristics.
Seronegativity, n (%) ≥1.0 OD units, n (%) p-value
By hospital HUPdH (Madrid) (N = 239) 162 (67.8) 11 (4.6)
–CHUAC (Corun˜a) (N = 256) 175 (68.4) 7 (2.7)
HUdB (Barcelona) (N = 236) 166 (70.3) 6 (2.5)
By  hospital
department
Pediatrics (N = 64) 41 (64.1) 2 (3.1)
0.60
Neonatology (N = 28) 19 (67.9) 2 (7.1)
Obstetrics (N = 59) 38 (64.4) 3 (5.1)
Internal Medicine (N = 79) 52 (65.8) 3 (3.8)
Surgery (N = 68) 50 (73.5) 1 (1.5)
Other (N = 433) 303 (70.0) 13 (3.0)
By  professional
level
Physicians (N = 219) 147 (67.1) 7 (3.2)
0.11
Nurses (N = 292) 207 (70.9) 8 (2.7)
Ancillary nurses (N = 198) 136 (68.7) 6 (3.0)
Midwives (N = 22) 13 (59.1) 3 (13.6)
N /N) ×
O re and
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w, total number of participants; n, number of participants in given category; % = (n
D  ≥1.0, indicative of current or recent infection; p-values calculated with chi-squa
The seropositivity amongst 18–24 year olds was  slightly lower
26.2%) than when compared to the other age groups (29.4–32.8%)
nd this could be due to persistence of these antibodies in those age
roups. There was no signiﬁcant difference seen between seropos-
tivity amongst males and females. The seroprevalence amongst
he different departments or professional categories was  not sig-
iﬁcant. The presence of anti-PT antibodies in an adult population
ould be due to previous immunization as well as previous infec-
ion.
In our study, no differences were found according to demo-
raphic characteristics or working characteristics showing that the
usceptibility status of this population is generalized. A different
spect to mention here is the lack of difference in seroprevalence
hen comparing vaccinated and non-vaccinated subjects, although
his could be caused by the fact that only a minority had received
accine during adulthood. Nevertheless in 40% of our sample, this
nformation was unknown and, therefore, this ﬁnding should be
nterpreted with caution.
Amongst the limitations of this study, it has to be mentioned
he lack of a clear correlate between anti-PT Ig levels and degree
f effective sero-protection level. Pertussis seroprevalence studies
ave been found useful in long term follow-up studies to assess the
volution of the disease in a population but conclusions based on
ross sectional approaches like this one are a challenge. The lack of
 known vaccination status is also a limitation of this study. Since
nterviews with the participants were the method for information
ollection, no vaccination record was consulted and participant’s
emory was the only source of information. There is a difﬁculty
hen comparing studies using different laboratory methods. Here,
he different results observed might include real differences in the
pidemiology of the disease as well as methodological variations.
espite different results observed across publications, the conclu-
ions are similar: the high level of susceptibility in this population
s a risk and efforts should be invested attempting to implement
he vaccine recommendations successfully.
The strengths of this study are that there have not been many
tudies conducted on this population; so the data is scarce when
t is critical point of contact with infants and therefore a potential
ource of infection for the most vulnerable. The study addresses
 true need of deep knowledge. Despite the limitations of the lab
ests, the study gives an idea of the situation at hospital level and it
s a heads-up regarding what recommendation should include. The
obility of healthcare professionals in hospitals is a clear drivero the need for wider recommendations that include all, not only
hose in contact with children, and the inclusion of three differ-
nt regions with different recommendations gives a better picture
hen compared to single hospital studies. 100; OD, optical density; Seronegativity, indicates absence of infection (OD <0.3);
 Fisher’s exact test.
Previously, there have been many cases of large outbreaks
in healthcare centers [27] where the ﬁrst case was a patient, a
healthcare personnel or a visitor [28,29]. Subsequently the disease
transmits in a large number of patients as well as healthcare per-
sonnel. This has previously been seen in one of the hospitals we
studied which caused them to change their pertussis vaccination
recommendations. These outbreaks have demonstrated the rela-
tive ease with which pertussis spreads within a healthcare setting.
Such trends have previously been observed in cases of inﬂuenza
outbreaks, which then led to increase in the vaccine acceptance rate
amongst clinicians and also went on to show signiﬁcant decreases
in nosocomial inﬂuenza infections amongst infants [30].
Immunization of healthcare personnel is therefore believed to
be the most effective way  to reduce morbidity due to pertussis.
Therefore, the Centers for Disease Control and Prevention has rec-
ommended that all healthcare personnel get vaccinated against
pertussis [31], while the National Advisory Committee for Immu-
nization in Canada recommends that all adults receive a single
booster dose of Tdap [32]. Recommendations exist in Belgium,
Germany, Luxemburg, Netherlands, and the United Kingdom. In
Austria, Finland, and Norway, the vaccine is recommended for
pediatricians and personnel in neonatal departments, whereas in
France it is only recommended for those directly involved in patient
care; the remaining 21 countries, have no recommendations in
place presently [33]. Mandatory healthcare personnel vaccination
has been suggested as being necessary to achieve high pertussis
vaccine coverage [33,34].
Given these rates of seronegativity amongst healthcare person-
nel, the large number of unknown vaccination status as well as the
similar trends seen in inﬂuenza studies, this study further strength-
ens the rationale for vaccination of healthcare workers against
pertussis.
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